CSI Market
Sign In | Register

Ra Pharmaceuticals Inc (RARX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RARX Annual Cash Flow →
From Ra Pharmaceuticals Inc through Dec 31 2018, changes in Dec 31 2019's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2019)
12 Months 		(Sep 30 2019) (Jun 30 2019) (Mar 31 2019) (Dec 31 2018)
Operating Activities
Income-102.69
Depreciation & amortization1.62
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation14.05
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Accretion Of Debt Issuance Costs And Discounts-
Temporary Equity Preferred Stock Tranche Rights Gain Loss On Fair Value Adjustment-
Gain Loss On Change In Fair Value Of Derivative Liability-
Increase Decrease In Prepaid Expense And Other Current Assets-
Change In Fair Value Of Preferred Stock Tranche Rights-
Operating Lease Expense-0.87
Increase Decrease In Operating Lease Liabilities-0.87
Increase Decrease In Prepaid Deferred Expense And Other Current Assets-4.96
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities7.02
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.07
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-87.36
Investing Activities
Capital Expenditures-0.87
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.87
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock144.52
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-213.07
Payments For Proposed Public Offering Costs-
Payments Of Preferred Stock Issuance Costs-
Proceeds From Disgorgement Of Stockholders Short Swing Profits-
Payment Of Common Stock Offering Costs-0.54
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents211.16
Restricted Cash And Cash Equivalents Noncurrent-1.33
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities143.40
Effect of exchange rate on cash flow55.17
Discontinued operations0.00
Free Cash Flow-88.23
Total Cash Flow55.17
4 historic quarters locked

Sign in to unlock the full Ra Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About RARX Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q
  • Filed with the SEC: n/a

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.

Figures are derived from filed reports and may be restated. Historical data is subject to revision.